{
    "2021-12-20": [
        [
            {
                "time": "2023-10-01",
                "original_text": "复星医药(02196.HK)子公司通过GMP符合性检查",
                "features": {
                    "keywords": [
                        "复星医药",
                        "子公司",
                        "GMP符合性检查"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "制药",
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "复星医药(02196.HK)子公司斯鲁利单抗注射液联合重组抗EGFR人源化单克隆抗体注射液用于治疗晚期实体瘤开展II期临床试验获批准",
                "features": {
                    "keywords": [
                        "复星医药",
                        "斯鲁利单抗",
                        "重组抗EGFR",
                        "临床试验",
                        "晚期实体瘤"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "制药",
                        "肿瘤治疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "复星医药(600196.SH)：斯鲁利单抗注射液、重组抗EGFR人源化单克隆抗体注射液获药品临床试验批准",
                "features": {
                    "keywords": [
                        "复星医药",
                        "斯鲁利单抗",
                        "重组抗EGFR",
                        "临床试验"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "制药",
                        "肿瘤治疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "复星医药(600196.SH)：斯鲁利单抗注射液联合HLX07治疗晚期实体瘤获准开展II期试验",
                "features": {
                    "keywords": [
                        "复星医药",
                        "斯鲁利单抗",
                        "HLX07",
                        "晚期实体瘤",
                        "II期试验"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "制药",
                        "肿瘤治疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "复星医药(600196.SH)子公司二车间硬胶囊生产线通过GMP符合性检查",
                "features": {
                    "keywords": [
                        "复星医药",
                        "子公司",
                        "硬胶囊生产线",
                        "GMP符合性检查"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "制药",
                        "生产"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "复星医药：子公司获药品临床试验批准",
                "features": {
                    "keywords": [
                        "复星医药",
                        "子公司",
                        "临床试验"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "制药",
                        "研发"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "抢占科创高地，面向全球招才引智!复星亮相首届全国博士后创新创业大赛",
                "features": {
                    "keywords": [
                        "复星",
                        "科创高地",
                        "全球招才引智",
                        "博士后大赛"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "创新",
                        "人才引进"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}